TheraCryf PLC
Company Profile
Business description
TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol, and other substance use disorders. It also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The Group also has an oncology programme in glioblastoma with SFX-01. It operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
9
Stocks News & Analysis
stocks
The World Cup stock you’ve never heard of
stocks
Chart of the Week: Can WiseTech shares finally bounce back?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,949.70 | 19.10 | -0.21% |
| CAC 40 | 8,326.62 | 73.96 | 0.90% |
| DAX 40 | 25,118.27 | 220.82 | 0.89% |
| Dow JONES (US) | 52,487.41 | 139.02 | 0.27% |
| FTSE 100 | 10,472.45 | 16.59 | -0.16% |
| HKSE | 24,030.18 | 169.28 | -0.70% |
| NASDAQ | 26,206.89 | 336.24 | 1.30% |
| Nikkei 225 | 68,635.59 | 891.74 | 1.32% |
| NZX 50 Index | 13,785.67 | 120.49 | 0.88% |
| S&P 500 | 7,543.64 | 60.93 | 0.81% |
| S&P/ASX 200 | 8,751.50 | 16.30 | -0.19% |
| SSE Composite Index | 4,036.59 | 65.71 | 1.65% |